<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        11-222-01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SALIPAX 20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FLUOXETINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        84.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ACINO PHARMA AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ACINO PHARMA AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ACINO PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The active substance in Salipax is Fluoxetine hydrochloride. Salipax acts on the central nervous system. This medicine is used to treat the following conditions: Adults: &bull; Major depressive episodes &bull; Obsessive-compulsive disorder &bull; Bulimia nervosa: Salipax is used alongside psychotherapy for the reduction of binge-eating and purging Children and adolescents aged 8 years and above: &bull; Moderate to severe major depressive disorder, if the depression does not respond to psychological therapy after 4-6 sessions. Salipax should be offered to a child or young person with moderate to severe major depressive disorder only in combination with psychological therapy.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">a. Do not take Salipax Salipax must not be taken if you are allergic to any of the ingredients contained in Salipax. Treatment with Salipax or with any other antidepressant should not be commenced in states with abnormally elevated mood, known as acute manic states. Salipax must not be taken together with certain medicines used to treat depression or Parkinson&rsquo;s disease ( so-called MAO inhibitors), since otherwise severe or&nbsp;even fatal reactions may occur (serotonin syndrome, see &ldquo;Possible side effects?&rdquo;). Salipax must not be taken before 14 days after the end of a treatment with an irreversible MAO inhibitor or 1 day after the end of treatment with a reversible MAO inhibitor. You must also wait at least 5 weeks after discontinuing Salipax before you take an MAO inhibitor. Switching from Salipax to an MAO inhibitor, and the other way around, may only be done under careful medical supervision. Salipax should not be used in the treatment of children under the age of 8 years. b. Take special care with Salipax Inform your doctor if you suffer from liver or kidney function disorders, problems with your blood pressure and heart, dilation of the pupils (mydriasis) or epilepsy. If a skin rash or other signs of an allergy occur during treatment with Salipax, contact your doctor without delay and stop taking the medicine. In diabetics, treatment with Salipax may make a dose adjustment of the insulin and/ or oral antidiabetic necessary. Diabetics should therefore consult their doctor regarding treatment with Salipax. Consult your doctor if you take certain antidepressants &ndash; so-called selective serotonin reuptake inhibitors (SSRI) or St. John&rsquo;s wort (contained in certain natural or herbal preparations), certain medicines used to treat migraine, lithium or L-tryptophan, since under treatment with these medicines there is an increased risk of serotonin syndrome (see &ldquo;Possible side effects?&rdquo;). If you take fluoxetine in combination with lithium, your doctor will check you more frequently. Tell your doctor or consult with him/her about any use of other medicines at the same time with this treatment such as sleeping pills, tranquillizers, antiepileptics, antidepressants, blood thinners and medicines used to treat irregular heartbeat (antiarrhythmics), as dose adjustments may be required. c. Taking other medicines, herbal or dietary &nbsp;supplements Combined use of other medicines, such as medication for heart rhythm disorders (antiarrhythmic agents), antipsy<br />chotics, tricyclic antidepressants, certain antibiotics, antimalarial agents, certain antihistamines, can cause heart rhythm problems, which may be serious. You must therefore tell your doctor if you are taking such medicines. Depression symptoms may get worse under treatment with Salipax. Contact your doctor in such cases. Taking medicines from the class to which Salipax belongs may rarely result in bleeding, for example in the skin, mucous membranes of the mouth, genital mucous membranes in women, in the gastrointestinal tract or in other organ systems. Contact your doctor right away if this occurs. Be very careful when using Salipax concomitantly with oral anticoagulants, medicines known to prolong bleeding time or influence blood platelet function (e.g. atypical neuroleptics such as clozapine, phenothiazine, most tricyclic antidepressants, acetylsalicylic acid, non-steroidal antirheumatics) or other substances that increase the risk of bleeding, or if you have previously suffered from bleeding. The medicine must not be discontinued suddenly and this may only be done in consultation with your doctor, since otherwise withdrawal symptoms may develop. d. Taking Salipax with food and drink You should avoid drinking alcohol during treatment with Salipax. This medicine may affect your reactions and your ability to drive or to use tools or machines. Tell your doctor or pharmacist if you suffer from other&nbsp;<br />&nbsp;illnesses, have any allergies or are taking or externally using any other medicines (including those purchased without a prescription!). e. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Pregnancy Talk to your doctor as soon as possible if you&lsquo;re pregnant, if you might be pregnant, or if you&lsquo;re planning to become pregnant. In babies whose mothers took fluoxetine during the first few months of pregnancy, there have been some studies describing an increased risk of birth defects affecting the heart. In the general population, about 1 in 100 babies are born with a heart defect. This increased to about 2 in 100&nbsp;babies in mothers who took fluoxetine. When taken during pregnancy, particularly in the last 3&nbsp;months of pregnancy, medicines like fluoxetine may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish. These symptoms usually begin during the first 24&nbsp;hours after the baby is born. If this happens to your baby you should contact your midwife and/or doctor immediately. It is preferable not to use this treatment during pregnancy unless the potential benefit outweighs the potential risk. Thus, you and your doctor may decide to gradually stop taking Salipax while you are pregnant or before being pregnant. However, depending on your circumstances, your doctor may suggest that it is better for you to keep taking Salipax. Caution should be exercised when used during pregnancy, especially during late pregnancy or just before giving birth since the following effects have been reported in new born children: irritability, tremor, muscle weakness, persistent crying, and difficulty in sucking or in sleeping. Breast-feeding Fluoxetine is excreted in breast milk and can cause side effects in babies. You should only breast-feed if it is clearly necessary. If breast-feeding is continued, your doctor may prescribe a lower dose of fluoxetine. Fertility Fluoxetine has been shown to reduce the quality of sperm in animal studies. Theoretically, this could affect fertility, but impact on human fertility has not been observed as yet. f. Driving and using machines This medicine may affect your reactions and your ability to drive or to use tools or machines. g. Important information about some of the&nbsp;<br />&nbsp;ingredients of Salipax Salipax contains 0.15 g lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Do not take more capsules than your doctor tells you. Swallow the capsules with a drink of water. Do not chew the capsules. Adults: The recommended dose is: &bull; Depression: The recommended dose is 1 capsule (20&nbsp;mg) daily. Your doctor will review and adjust your dosage if necessary within 3 to 4 weeks of the start of treatment. If required, the dosage can be gradually increased up to a maximum of 3 capsules (60&nbsp;mg) daily. The dose should be increased carefully to ensure that you receive the lowest effective dose. You may not feel better immediately when you first start taking your medicine for depression. This is usual because an improvement in depressive symptoms may not occur until after the first few weeks. Patients with depression should be treated for at least 6 months. &bull; Bulimia nervosa: The recommended dose is 3&nbsp;cap sules (60 mg) daily. &bull; Obsessive-compulsive disorder: The recommended dose is 1 capsule (20 mg) daily. Your doctor will review and adjust your dosage if necessary after 2 weeks of treatment. If required, the dosage can be gradually increased up to a maximum of 3 capsules (60 mg) daily. If no improvement is noted within 10 weeks, your doctor will reconsider your treatment. Use in children and adolescents aged 8 to 18 years with depression: Treatment should be started and be supervised by a specialist. The starting dose is 10 mg/day (given as 2.5&nbsp;ml of&nbsp;Salipax oral solution). After 1 to 2 weeks, your doctor&nbsp;<br />may increase the dose to 20 mg/day. The dose should be increased carefully to ensure that you receive the lowest effective dose. Lower weight children may need lower doses. If there is a satisfactory response to treatment, your doctor will review the need for continuing treatment beyond 6 months. If you have not improved within 9&nbsp;weeks, your doctor will reassess your treatment. Elderly: Your doctor will increase the dose with more caution and the daily dose should generally not exceed 2 capsules (40&nbsp;mg). The maximum dose is 3 capsules (60 mg) daily. Liver impairment: If you have a liver problem or are using other medication that might affect Salipax, your doctor may decide to prescribe a lower dose or tell you to use Salipax every other day. a. If you take more Salipax than you should &bull; If you take too many capsules, go to your nearest hospital emergency department (or casualty) or tell your doctor straight away. &bull; Take the pack of Salipax with you if you can. Symptoms of overdose include: nausea, vomiting, seizures, heart problems (like irregular heart beat and cardiac arrest), lung problems and change in mental condition ranging from agitation to coma. b. If you forget to take Salipax &bull; If you miss a dose, do not worry. Take your next dose the next day at the usual time. Do not take a double dose to make up for a forgotten dose. &bull; Taking your medicine at the same time each day may help you to remember to take it regularly. c. If you stop taking Salipax &bull; Do not stop taking Salipax without asking your doctor first, even when you start to feel better. It is important that you keep taking your medicine. &bull; Make sure you do not run out of capsules.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">You may not feel better right away when you start taking your medicine to treat depression. This is normal, since improvement of depressive symptoms may not begin until after the first couple of weeks of treatment. Symptoms of depression may include thoughts of selfinjury or suicide. These symptoms of depression may become worse during the first weeks of treatment until the full antidepressant effect is established. Please tell your doctor immediately or go to the nearest hospital if you have any very unpleasant thoughts or experiences during treatment, in particular suicidal thoughts or thoughts about hurting yourself. The risk of&nbsp;&nbsp;suicide is particularly increased in young adults (&lt;25&nbsp;years). The risk of suicidal behaviour is also raised in children and adolescents, for which reason treatment with Salipax is not recommended (see also &ldquo;When is caution needed while taking Salipax?&rdquo;). The risk of such thoughts is greater if your depression was very severe before the treatment, if your depression is getting worse or if you suffer from pronounced restlessness, panic attacks or sleep disturbances. Please tell your doctor immediately or go to the nearest hospital if you experience such symptoms. Other psychiatric diseases for which Salipax is prescribed may also involve an increased risk of the experiences described above (thoughts of self-injury or suicide). The&nbsp;same precautions therefore apply if you have other psychiatric illnesses. Side effects that occur at the beginning of treatment usually get better in the course of treatment. The most frequent side effects during treatment with Salipax are: headache, nausea, sleeplessness, tiredness and diarrhoea. The following side effects may also occur: Common: nervousness, sleep disorders, restlessness, tension, anxiety, attention deficit disorder, taste disorders, lethargy, sleepiness, dizziness, tremor, unusual dreams (including nightmares), reduction of libido, vomiting, belching, dry mouth, reduced appetite, weight loss, impaired vision, racing heart, blushing, yawning, skin rash, hives, itching, increased sweating, frequent urination, gynaecological bleeding, erection problems, ejaculation disorders, nervousness, chills, liver function disorders. Uncommon: elevated or euphoric mood, abnormal thoughts, abnormal orgasm, grinding of teeth, movement disorders (dyskinesia), muscle twitching, dilation of pupils, difficulty breathing, flatulence, hair loss, increased tendency to bruising, cold sweat, urination disorders, sexual function disorders (sometimes persisting after treatment is over), malaise, discomfort, feeling of heat, feeling of cold, tightness around heart (angina pectoris), heart attack, circulatory and blood pressure disorders. Reported rarely or in isolated cases: States of excitation, hallucinations, confusion, seizures, urine retention, prolonged erection, menstrual disorders, breast enlargement, flow of human milk, heart rhythm disorders, vein inflammation, changes in blood count, difficulty swallowing, bleeding in stomach / intestine, bleeding in skin or mucous membranes, nosebleed, memory disorders. Rashes occasionally occur which may be very rarely accompanied by joint pain and fever. Serious impairment of blood flow has been observed very rarely in patients with rashes. This is probably linked to vasculitis. Allergic (hypersensitivity) reactions occur rarely. These manifest themselves as, for example, an itchy rash, hives, asthma or allergic swellings of the skin and mucosa. If&nbsp;you experience any of these symptoms, consult your doctor immediately and discontinue the medication. Please contact your doctor without delay if you experience reddened skin, skin reactions, blister formation or skin peeling. This reaction is very rare. Disturbances to the fluid and salt balance, e.g. with confusion, convulsions, oedema (swelling resulting from fluid collection in the tissue spaces, e.g. of the skin and mucosa) occur in rare cases. A further side effect, so-called serotonin syndrome, which occurs in particular in combination with certain other medicines (see &ldquo;When is caution needed while taking Salipax?&rdquo;) takes the form of reduced awareness, muscle stiffness, muscle tremor, twitching and fever. If you experience this you must consult your doctor without delay. If side effects occur which you suspect are related to treatment with Salipax, please inform your doctor. If you notice any side effects not described here, you&nbsp;should tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep this medicine out of the sight &amp; reach of children. Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">1 capsule of Salipax capsule contains fluoxetine hydrochloride, equivalent to 20 mg fluoxetine, the colorants quinoline yellow (E 104) and indigo carmine (E 132), and other excipients.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Capsules, 20 mg: Packs of 14, 30 and 100 capsules. Not all packs may be marketed 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Marketing Authorisation Holder: Acino Pharma AG, Liesberg, Switzerland Manufacturer: Acino Pharma AG, Aesch, Switzerland&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2018 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="ltr">&nbsp;المادة الفعالة في ساليباكس هي هيدروكلوريد الفلوكسيتين. يعمل ساليباكس على الجهاز العصبي المركزي. واء لعلاج الحالات الآتية:َّستخدم هذا الدُي البالغون: نوبات الاكتئاب الكبرى &bull; اضطراب الوسواس القهري &bull; ستخدم ساليباكس بمصاحبة العلاج النفسي للحد من الأكل ُ النهام العصبي ي &bull; القهري و التطهير -أو التفريغ. أعوام فأكثر:8الأطفال والمراهقون ممن يبلغون &nbsp;الاضطراب الاكتئابي الكبير المعتدل إلى الشديد، في حال لم يستجب الاكتئاب &bull; أو ٍ جلسات. لا ينبغي تقديم ساليباكس لطفل6-4للعلاج النفسي بعد َّ بمصاحبة لاِ يافع مصاب باضطراب اكتئابي كبير معتدل إلى شديد إ ٍلشخص العلاج النفسي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">&nbsp;لا تتناول ساليباكس في الحالات الآتية: &nbsp;أ. يجب عدم تناول ساليباكس إذا كنت تعاني من حساسية تجاه أي من المكونات الموجودة بساليباكس. ينبغي عدم بدأ العلاج بساليباكس أو بأي مضاد آخر عرف بحالات ُللاكتئاب في الحالات المصابة بارتفاع غير طبيعي بالحالة المزاجية، ي الهوس الحادة. ستخدم لعلاج الاكتئاب أو ُيجب عدم تناول ساليباكس بمصاحبة أدوية معينة ت سمى بمثبطات أكسيداز أحادي ُاش (مرض باركنسون) (ما يَّمرض الشلل الرع ونين، ُوتُ لاَّ فقد تحدث تفاعلات شديدة أو حتى مميتة (متلازمة السيرِالأمين)، وإ حتملة&quot;).ُانظر قسم &quot;الآثار الجانبية الم ا على نهاية العلاج بمثبط ً يوم14يجب عدم تناول ساليباكس قبل مرور أكسيداز أحادي الأمين غير الارتدادي أو بعد يوم واحد من انتهاء العلاج بمثبط &nbsp;أسابيع على 5أكسيداز أحادي الأمين الارتدادي. كما يجب عليك الانتظار لمد الأقل بعد وقف ساليباكس قبل أن تتناول أحد مثبطات أكسيداز أحادي الأمين. يمكن الانتقال من ساليباكس لأحد مثبطات أكسيداز أحادي الأمين والعكس فقط تحت إشراف طبي دقيق. 8ينبغي عدم استخدام ساليباكس في علاج الأطفال ممن تقل أعمارهم عن أعوام. ا مع ساليباكس &nbsp;ًّا خاصً ب. توخ حذر لى، مشاكل ُأبلغ طبيبك إذا كنت تعاني من اضطرابات بوظائف الكبد أو الك ع. َّم وبالقلب لديك، توسع حدقتي العين أو الصَّبضغط الد صبت بطفح جلدي أو في حال ظهور علامات أخرى للحساسية أثناء العلاج ُإذا أ واء. بالنسبة َّبساليباكس، فاتصل بطبيبك دون تأخير وتوقف عن تناول الد ؤدي العلاج بساليباكس إلى ضرورة تعديل جرعة الأنسولين ُي، قد يِرَّكُّلمرضى الس ؤخذ عن طريق الفم. ولذلك ينبغي على ُو/ أو أدوية علاج مرض السكري التي ت ي استشارة طبيبهم فيما يخص العلاج بساليباكس.ِرَّكُّمرضى الس سمى بمثبطات ُ معينة -ما يٍاستشر طبيبك إذا كنت تتناول مضادات اكتئاب &quot; أو نبتة سانت جون (الموجودة SSRIإعادة امتصاص السيروتونين الانتقائية &quot; ستخدم ُفي بعض المستحضرات الطبيعية أو العشبية)، أو بعض الأدوية التي ت لعلاج الصداع النصفي، أو الليثيوم، أو إل- تريبتوفان؛ إذ إن الخضوع للعلاج ونين (انظر قسم: ُوتُبهذه الأدوية قد يزيد من مخاطر حدوث متلازمة السير &quot;آثار جانبية محتملة&quot;). إذا تناولت فلوكسيتين بمصاحبة الليثيوم، فسيقوم ا.ًطبيبك بفحصك بشكل أكثر تكرار أخبر طبيبك/ طبيبتك أو استشره/ استشرها بشأن أي استخدام لأدوية أخرى زامن مع هذا العلاج مثل: الحبوب المنومة، المهدئات، مضادات الصع، َّبالت ستخدم لعلاج عدم ُم والأدوية التي تَّمضادات الاكتئاب، الأدوية المسيلة للد انتظام ضربات القلب (الأدوية المضادة لاضطرابات النظم القلبي)، فقد يكون وري إجراء تعديلات بالجرعة. َّ من الضر شبية أو مكملات غذائية ُل أدوية أخرى، عُ ج. تناو قد يتسبب الاستخدام بمصاحبة أدوية أخرى مثل أدوية اضطرابات النظم القلبي، مضادات الذهان، مضادات الاكتئاب ثلاثية الحلقات، مضادات حيوية معينة، الأدوية المضادة للملاريا، مضادات هيستامين معينة في مشاكل بالنظم القلبي، والتي قد تكون خطيرة. لذلك يجب عليك إبلاغ طبيبك إذا كنت تتناول مثل هذه الأدوية. قد تتدهور أعراض الاكتئاب أثناء الخضوع للعلاج بساليبكس. اتصل بطبيبك في مثل هذه الحالات. سبب حدوث ُا ما يًتناول أدوية من الفئة التي ينتمي إليها ساليباكس نادر نزيف، على سبيل المثال بالجلد، أغشية الفم المخاطية، الأغشية المخاطية للأعضاء التناسلية لدى السيدات، في الجهاز الهضمي أو في أنظمة عضوية&nbsp;<br />أخرى. اتصل بطبيبك في الحال إذا حدث ذلك. خثر َّزامن مع مضادات التَّتوخى الحذر الشديد عند استخدام ساليباكس بالت عرف بإطالتها لزمن النزيف أو بتأثيرها على وظائف ُالفموية، أو الأدوية التي ت الصفائح الدموية (على سبيل المثال: مضادات الذهان غير النمطية مثل: كلوزابين، فينوثيازين، أغلب مضادات الاكتئاب ثلاثية الحلقات، حمض أسيتيل الساليسيليك، الأدوية المضادة للروماتيزم غير الستيرويدية) أو المواد الأخرى التي تزيد من خطر حدوث نزيف، أو إذا عانيت من قبل من نزيف. َّ لاِشاور مع طبيبك وإَّواء فجأة ومن الممكن وقفه فقط بالتَّيجب عدم وقف الد صاب بأعراض انسحاب.ُفقد ت ل ساليباكس مع الأطعمة والمشروبات ُ د. تناو ينبغي عليك تجنب شرب الكحوليات أثناء العلاج بساليباكس. واء على استجاباتك وقدرتك على القيادة أو على استخدام َّؤثر هذا الدُقد ي الأدوات أو الآلات. رجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تعاني من أي أمراض أخرى، ُي ا- أية أدوية ًّا خارجيًأو أي حساسية، أو إذا كنت تتناول أو تستخدم -استخدام أخرى (بما في ذلك الأدوية التي يتم الحصول عليها بدون وصفة طبية!). ه. الحمل والرضاعة الطبيعية &nbsp;حامل أو تخططين للحمل، ِا، أو تعتقدين أنكًً أو مرضع حاملا ِإذا كنت واء.َّفاستشيري طبيبك أو الصيدلي الخاص بك قبل تناول هذا الد الحمل ً، أو إذا كان من المحتمل ثي إلى طبيبك في أسرع وقت ممكن إذا كنت حاملا َّتحد تخططين للحمل.ًِ، أو إذا كنت أن تكوني حاملا ضع ممن تناولت ُّجريت على الأطفال الرُأوضحت بعض الدراسات التي أ أمهاتهم فلوكسيتين أثناء الأشهر الأولى من الحمل تزايد مخاطر العيوب الخلقية &nbsp;100ولد طفل واحد من بين كل ُؤثر على القلب. في الشريحة العامة، يُالتي ت ا. زادت هذه النسبة؛ لتصل إلى طفلين من بين كل ًطفل بعيب بالقلب تقريب طفل ممن تناولت أمهاتهم فلوكسيتين.100 الأدوية َّ في الأشهر الثلاثة الأخيرة من الحمل، فإنًلها أثناء الحمل، خاصةُعند تناو ضع، ُّالمماثلة لفلوكسيتين قد تزيد من خطر حدوث حالة خطيرة في الأطفال الر &quot;، مما PPHNم الرئوي المستمر للمولود الجديد &quot;َّمى ارتفاع ضغط الدَسُت ً إلى اللون الأزرق. عادة ما يجعل الطفل يتنفس بصورة أسرع ويبدو لونه مائلا ساعة الأولى بعد ولادة الطفل. إذا حدث هذا 24تبدأ هذه الأعراض أثناء الـ ا.ً فورِ و/ أو طبيبكِة بكَّة الخاصَلِ الاتصال بالقابِلطفلك فيجب عليك َّ إذا كانت الفوائد المتوقعة لاِل عدم استخدام هذا العلاج أثناء الحمل إَّفضُي ا ًّوقف تدريجيَّ التِ وطبيبكِالي، قد تقررين أنتَّتفوق المخاطر المحتملة. وبالت على حالتك، قد يقترح ًعن تناول ساليباكس أثناء الحمل أو قبله. مع ذلك، بناء طبيبك أنه من الأفضل لك الاستمرار في تناول ساليباكس. أثناء المراحل الأخيرة ًينبغي توخي الحذر عند استخدامه أثناء الحمل، خاصة الية في الأطفال حديثي َّمن الحمل أو قبيل الإنجاب؛ إذ تم الإبلاغ عن الآثار الت الولادة: هياج، ارتعاش، ضعف العضلات، بكاء مستمر وصعوبة في الامتصاص أو في النوم. ضاعة الطبيعيةَّالر ا جانبية في الأطفال الرضع. ينبغي ًز فلوكسيتين في لبن الأم وقد يسبب آثارَفرُي عليك ممارسة الرضاعة الطبيعية فقط إذا كانت هناك ضرورة ملحة. إذا ة، قد يصف لك طبيبك جرعة أقل من َّاستمررت بممارسة الرضاعة الطبيعي فلوكسيتين. الخصوبة جريت على الحيوانات أن فلوكسيتين يقلل من جودة ُاتضح في الدراسات التي أ َّ أنه لم تتم دراسة لاِؤثر ذلك على الخصوبة، إُا، قد يًّالحيوانات المنوية. نظري تأثيره على الخصوبة لدى البشر حتى الآن. و. القيادة واستخدام الآلات واء على استجاباتك وقدرتك على القيادة أو على استخدام َّؤثر هذا الدُقد ي الأدوات أو الآلات. ة عن بعض مكونات ساليباكسَّ ز. معلومات هام جرام من اللاكتوز.0.15يحتوي ساليباكس على إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات، فاتصل به قبل واء. َّتناول هذا الد&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ساليباكس .4 واء بالضبط كما أخبرك طبيبك أو الصيدلي الخاص بك. راجع َّتناول دائمًا هذا الد ل ُا من كيفية الاستخدام. لا تتناوًطبيبك أو الصيدلي الخاص بك إذا لم تكن متأكد كمية من الكبسولات أكثر من التي وصفها لك طبيبك. ابتلع الكبسولات مع بعض الماء. لا تمضغ الكبسولات. البالغون: الجرعة الموصى بها هي: ا. سيراجع ًّ مجم) يومي20وصى بها هي كبسولة واحدة (ُ الاكتئاب: الجرعة الم &bull; أسابيع من بدء 4 إلى 3طبيبك جرعتك وسيعدلها إذا لزم الأمر في غضون &nbsp;60 كبسولات (3ا حتى ًّن زيادة الجرعة تدريجيِكُالعلاج. إذا لزم الأمر، يم أكد من تلقيك َّا بحد أقصى. ينبغي زيادة الجرعة بحذر للتًّمجم) يومي الة. قد لا تشعر بتحسن على الفور عند بدءك تناول دواء َّأقل جرعة فع حسن في الأعراض َّ التَّا؛ لأنًّا عاديًعد ذلك أمرُالاكتئاب الخاص بك لأول مرة. ي لاَّ بعد الأسابيع القليلة الأولى. ينبغي علاج مرضى ِالاكتئابية قد لا يحدث إ أشهر على الأقل.6الاكتئاب لمدة ا.ًّ مجم) يومي60 كبسولات (3وصى بها هي ُ النهام العصبي: الجرعة الم &bull; 20وصى بها هي كبسولة واحدة (ُ اضطراب الوسواس القهري: الجرعة الم &bull; ا. سيراجع طبيبك جرعتك وسيعدلها إذا لزم الأمر بعد أسبوعين ًّمجم) يومي 60 كبسولات (3ا حتى ًّن زيادة الجرعة تدريجيِكُمن العلاج. إذا لزم الأمر، يم أسابيع، فسيعيد 10 في غضون ٌظ تحسنَلاحُا بحد أقصى. إذا لم يًّمجم) يومي ظر في علاجك.َّطبيبك الن الاستخدام في الأطفال والمراهقين ممن يعانون من الاكتئاب ممن تبلغ ا: ً عام18 إلى 8أعمارهم ينبغي بدء العلاج والإشراف عليه من قبل طبيب متخصص. تبلغ جرعة البدء &nbsp;مللي لتر من ساليباكس محلول 2.5 مجم/ اليوم (يتم إعطاؤها في هيئة 10 20فموي). بعد أسبوع إلى أسبوعين، قد يزيد طبيبك من الجرعة لتصل إلى الة. َّأكد من تلقيك أقل جرعة فعَّمجم/ اليوم. ينبغي زيادة الجرعة بحذر؛ للت قد يحتاج الأطفال ذوو الوزن المنخفض جرعات أقل. إذا كان هناك استجابة &nbsp;أشهر. إذا 6رضية للعلاج، سيراجع طبيبك الحاجة إلى مواصلة العلاج لأكثر من ُم أسابيع، سيعيد طبيبك تقييم علاجك.9لم تتحسن في غضون كبار السن: َّ تتجاوز الجرعة لاَسيزيد طبيبك من الجرعة مع توخي حذر أكبر وينبغي أ 60 كبسولات (3 مجم) بشكل عام. الجرعة القصوى هي 40اليومية كبسولتين ( ا.ًّمجم) يومي القصور الكبدي: ؤثر ُإذا كنت تعاني من مشكلة بالكبد أو إذا كنت تستخدم أدوية أخرى قد ت على ساليباكس، فقد يقرر طبيبك وصف جرعة أقل أو إخبارك باستخدام ساليباكس كل يومين. إذا تناولت كمية أكثر مما يجب من ساليباكس &nbsp;أ. وارئ َّ إذا تناولت كمية كبيرة من الكبسولات، فاذهب إلى قسم الط &bull; ا.ً(الحوادث) بأقرب مستشفى لك أو أخبر طبيبك فور خذ معك عبوة ساليباكس إذا استطعت. &bull; ائدة: الغثيان، القيء، نوبات تشنجية،&nbsp; مشاكل َّ تشمل أعراض الجرعة الز&nbsp;</p><p>بالقلب (مثل عدم انتظام ضربات القلب والسكتة القلبية)، مشاكل بالرئة ياج والغيبوبة.ِا بالحالة العقلية تتراوح بين الهًوتغير ب. إذا أغفلت تناول ساليباكس الي في َّالية في اليوم التَّل جرعة، فلا تقلق. تناول جرعتك التُ إذا أغفلت تناو &bull; الموعد المعتاد. لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها. ل دوائك في الوقت نفسه من كل يوم على أن تتذكّر تناوله ُساعدك تناوُ قد ي &bull; بشكل منتظم. ج. إذا توقفت عن تناول ساليباكس<br />ً، حتى عندما تبدأ &nbsp;لا تتوقف عن تناول ساليباكس دون استشارة طبيبك أولا &bull; بالشعور بتحسن. من الهام أن تستمر في تناول دوائك. تأكد من عدم نفاذ كبسولاتك.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">قد لا تشعر بتحسن على الفور عند بدءك تناول دواء علاج الاكتئاب الخاص ا؛ لأن التحسن في الأعراض الاكتئابية قد لا يبدأ ًّا عاديًعد ذلك أمرُبك. ي لاَّ بعد انقضاء الأسابيع القليلة الأولى من العلاج.ِبالحدوث إ ا تحض على إيذاء النفس أو الانتحار. قد ًقد تتضمن أعراض الاكتئاب أفكار تتفاقم أعراض الاكتئاب هذه أثناء الأسابيع الأولى من العلاج إلى أن يسري المفعول الكامل لمضادات الاكتئاب. رجى إبلاغ طبيبك على الفور أو الذهاب إلى أقرب مستشفى إذا راودتك ُي ة الأفكار َّأي أفكار بالغة السوء أو تعرضت لمواقف بغيضة أثناء العلاج، خاص ٍالانتحارية أو الأفكار التي تحضك على إيذاء نفسك. يزيد خطر الانتحار بشكل ا). كما يزيد خطر السلوك الانتحاري في الأطفال ً عام25خاص في اليافعين (&lt; ا &quot;متى ينبغي توخي ًوصى بالعلاج بساليباكس (انظر أيضُوالمراهقين؛ لذلك لا ي الحذر عند تناول ساليباكس؟&quot;). ا للغاية قبل العلاج، أو إذا ًوتزيد مخاطر مثل تلك الأفكار إذا كان اكتئابك شديد كان الاكتئاب لديك يتفاقم، أو إذا عانيت من تململ (شعور بعدم ارتياح) جلي، رجى إخبار طبيبك على الفور ُأو من نوبات هلع، أو من اضطرابات في النوم. ي صبت بمثل تلك الأعراض.ُأو الذهاب إلى أقرب مستشفى لك إذا أ ا ًا متزايدًقد تتضمن الأمراض النفسية الأخرى التي يوصف لها ساليباكس خطر لما تم ذكره أعلاه (أفكار تحض على إيذاء النفس أو الانتحار). ومن ثم تنطبق ا بأمراض نفسية أخرى.ًالاحتياطات ذاتها إذا كنت مصاب عادًة ما تتحسن الآثار الجانبية التي تحدث عند بدء العلاج أثناء العلاج. ا أثناء العلاج بساليباكس الآتي:ًتشمل الآثار الجانبية الأكثر تكرار .ً ا وإسهالا ًا)، تعبًالصداع، الغثيان، عدم القدرة على النوم (أرق الية:َّا الآثار الجانبية التًقد تحدث أيض شائعة: العصبية، اضطرابات النوم، التململ (الشعور بعدم ارتياح)، التوتر، القلق، اضطراب نقص الانتباه، اضطراب التذوق، الخمول، النعاس، الدوخة، الارتعاش، أحلام غريبة (بما في ذلك الكوابيس)، قلة الرغبة الجنسية، التقيؤ، التجشؤ، جفاف الَفم، انخفاض الشهية، فقدان الوزن، قصور الرؤية، تسارع ضربات القلب، احمرار الوجه، التثاؤب، طفح جلدي، شرى (أرتكاريا)، الحكة، تزايد التعرق، تكرار التبول، نزيف لدى النساء، مشاكل بالانتصاب، اضطرابات بالقذف، العصبية، قشعريرة، اضطرابات بوظائف الكبد.<br />غير شائعة: ارتفاع الحالة المزاجية أو المزاج المبتهج غير المبرر، أفكار غير طبيعية، نشوة جنسية غير طبيعية، صريف الأسنان، اضطرابات بالحركة (خلل الحركة)، نفس، انتفاخ البطن بالغازات، َّالانتفاض العضلي، توسع حدقة العين، صعوبة الت تساقط الشعر، تزايد قابلية الإصابة بكدمات، عرق بارد، اضطرابات بالتبول، ك، ُّعَوَا تستمر لما بعد انتهاء العلاج)، تًاضطرابات بالوظائف الجنسية (أحيان الانزعاج، شعور بالحر، شعور بالبرد، ضيق حول القلب (الذبحة الصدرية)، نوبة قلبية، اضطرابات بالدورة الدموية أو بضغط الدم. بلغ عنها في حالات فردية: حالات من ُ نادر أو أٍأعراض تم الإبلاغ عنها بشكل الإثارة أو الحماس، الهلاوس، الارتباك/ الالتباس، نوبات تشنجية، احتباس البول، م الثدي، تدفق ُّضخَانتصاب العضو الذكري لمدة طويلة، اضطرابات الطمث، ت م، َّاللبن، اضطرابات النظم القلبي، التهاب الأوردة، تغييرات في تعداد خلايا الد صعوبة البلع، نزيف بالمعدة/ الأمعاء، نزيف بالجلد أو بالأغشية المخاطية، نزيف الأنف، اضطرابات بالذاكرة. ا جدا ما يصاحبه ألم بالمفاصل وحمى. تمت ًا ما يحدث طفح جلدي ونادرًأحيان م بشكل نادر للغاية في المرضى المصابين بطفح َّملاحظة قصور شديد بتدفق الد موية.َّجلدي. قد يكون هذا ذا صلة بالتهاب الأوعية الد ا ما تحدث تفاعلات حساسية (فرط حساسية). وهي تظهر نفسها، على ًنادر سبيل المثال، على هيئة طفح جلدي مصحوب بحكة، أو شرى (أرتكاريا)، أو ربو، &nbsp;من ٍّا إذا عانيت من أيًأو تورم بالجلد والأغشية المخاطية . أخبر طبيبك فور م بوقف العلاج.ُهذه الآثار وق رجى الاتصال بطبيبك دون تأخير إذا عانيت من احمرار بالجلد، تفاعلات ُي ا.ًّا جدًعد هذا التفاعل نادرُجلدية، تكون بثور أو تقشر الجلد. ي في حالات نادرة تحدث اضطرابات بتوازن السوائل والأملاح، على سبيل المثال: م ناجم عن تجمع السوائل في مناطق ُّرَمع الارتباك، التشنجات، الوذمة (تو الأنسجة، على سبيل المثال: بالجلد والأغشية المخاطية). ونين، والذي يحدث ُوتُسمى بمتلازمة السيرُيظهر الأثر الجانبي الإضافي الذي ي خاص بمصاحبة أدوية معينة أخرى (انظر &quot;متى ينبغي توخي الحذر ٍبشكل بالوعي، تصلب العضلات، ارتعاش ٍعند تناول ساليباكس؟&quot;) على هيئة انخفاض العضلات، الانتفاض العضلي والحمى. يجب استشارة طبيبك دون تأخير إذا عانيت من هذا الأثر. رجى إبلاغ ُصبت بآثار جانبية تشتبه بأنها ذات صلة بعلاج ساليباكس، يُإذا أ طبيبك. يجب عليك إخبار طبيبك أو الصيدلي الخاص بك إذا لاحظت أية آثار جانبية شرة.َّغير مذكورة في هذه الن&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ&nbsp;هذا الدواء&nbsp;بعيدا&nbsp;رؤية ومتناول الأطفال.&nbsp;</p><p>لا يخزن&nbsp;في درجة حرارة&nbsp;تتعدى 30 درجة مئوية&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">تحتوي كل كبسولة من ساليباكس على هيدروكلوريد الفلوكسيتين، ما يعادل ) وإنديجو E 104( مجم من فلوكسيتين، والمواد الملونة الكينولين الأصفر 20 )، وسواغات أخرى.E 132(كارمين وم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">&nbsp;مجم:20كبسولات، &nbsp;كبسولة.100، و30، و14عبوات بها قد لا يتم تسويق جميع أحجام العبوات</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التسويق:&nbsp;أسينو فارما إيه جي، ليزبيرج، سويسرا</p><p>وجهة التَّصنيع:&nbsp;أسينو فارما إيه جي، ايش، سويسرا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            2018يونيو  
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SalipaxTM 20 mg, Capsules

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active substance: Fluoxetine (as fluoxetine hydrochloride). Excipients with known effect: Each capsule contains 146,60 mg lactose monohydrate For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 capsule contains: 20 mg fluoxetine (as fluoxetine hydrochloride).

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Adults: Major depressive episodes Obsessive-compulsive disorder<br />Bulimia nervosa: Salipax is used alongside psychotherapy for the reduction of bingeeating and purging Children and adolescents aged 8 years and above: Moderate to severe major depressive disorder, if the depression does not respond to psychological therapy after 4-6 sessions. Prozac should be offered to a child or young person with moderate to severe major depressive disorder only in combination with psychological therapy.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Adults Depression The recommended daily dose is 20 mg of fluoxetine. Although fluoxetine was administered in doses up to 80 mg/day in clinical trials, the clinical effect of 20 mg/day is comparable to that of the higher dose. The dose can be increased stepwise (20 mg) after several weeks, if required in particular cases. The maximum dose is 80 mg of fluoxetine per day. If the daily dose exceeds 20 mg, it should be divided over the day (e.g. in the morning and in the evening). In special cases (see below), for dose reduction the administration frequency may be reduced, e.g. 20 mg every other day. Bulimia nervosa The recommended dose is 60 mg per day. Obsessive-compulsive disorder Adults and the elderly: The recommended dose is 20mg daily. Although there may be an increased potential for undesirable effects at higher doses, in some patients, if after two weeks there is insufficient response to 20mg, the dose may be increased gradually up to a maximum of 60mg. If no improvement is observed within 10 weeks, treatment with fluoxetine should be reconsidered. If a good therapeutic response has been obtained, treatment can be continued at a dosage adjusted on an individual basis. While there are no systematic studies to answer the question of how long to continue fluoxetine treatment, OCD is a chronic condition and it is reasonable to consider continuation beyond 10 weeks in responding patients. Dosage adjustments should be made carefully on an individual patient basis, to maintain the patient at the lowest effective dose. The need for treatment should be reassessed periodically. Some&nbsp;<br />clinicians advocate concomitant behavioural psychotherapy for patients who have done well on pharmacotherapy. Long-term efficacy (more than 24 weeks) has not been demonstrated in OCD. Method of administration Fluoxetine may be taken independently of meals. Dosage/Use Paediatric population - Children and adolescents aged 8 years and above (Moderate to severe major depressive episode) Treatment should be initiated and monitored under specialist supervision. The starting dose is 10mg/day given as 2.5ml of fluoxetine oral solution. Dose adjustments should be made carefully, on an individual basis, to maintain the patient at the lowest effective dose. After one to two weeks, the dose may be increased to 20mg/day. Clinical trial experience with daily doses greater than 20mg is minimal. There is only limited data on treatment beyond 9 weeks. Lower-weight children: Due to higher plasma levels in lower-weight children, the therapeutic effect may be achieved with lower doses. For pediatric patients who respond to treatment, the need for continued treatment after 6 months should be reviewed. If no clinical benefit is achieved within 9 weeks, treatment should be reconsidered. In elderly patients and patients with low body weight, a daily dose of 60 mg of fluoxetine should not be exceeded; a lower dose is recommended. Renal impairment: Repeated administration of fluoxetine leads to accumulation in renal impairment. Adjustment of the dose is generally required. Hepatic impairment: Because its metabolism is prolonged, the planned dose of fluoxetine must be reduced. This means, e.g., 20 mg every other day. Concomitant treatments: A lower dose or less frequent administration should be considered in patients who are on several medications. Withdrawal symptoms on discontinuing treatment with selective serotonin re-uptake inhibitors (SSRIs): Withdrawal symptoms have been reported when SSRI treatment has been discontinued abruptly, although available findings do not indicate that this is due to dependence. Common symptoms include dizziness, sleep disturbance, paraesthesia, headache, anxiety and nausea. The majority of these reactions are mild and self-limiting. Discontinuation of fluoxetine has been associated with symptoms of this nature. Therefore, when discontinuing treatment with Salipax, the dose should be tapered off gradually to reduce&nbsp;<br />the risk of withdrawal symptoms (see also &ldquo;Warnings and precautions: Withdrawal reactions on discontinuing treatment with an SSRI&rdquo;).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to fluoxetine or any of the excipients of Salipax. Treatment with fluoxetine should not be initiated during states of acute mania. Monoamine oxidase (MAO) inhibitors (irreversible and reversible): combined use of fluoxetine and MAO inhibitors must be avoided. There have been reports of serious reactions associated with the combined use of fluoxetine and MAO inhibitors or serotonergic antidepressants (such as clomipramine, preparations containing Hypericum perforatum). Symptoms of an interaction with an MAO inhibitor include: hyperthermia, muscle rigidity, myoclonus, autonomic nervous system instability with the possibility of rapid fluctuations of pulse and respiration, as well as mental status changes including confusion, irritability and extreme agitation progressing to delirium and coma. Since fluoxetine and its active metabolite have a long half-life, there should be an interval of at least 5 weeks (about 5 norfluoxetine half-lives) between discontinuation of Salipax and onset of treatment with MAO inhibitors. Administration of MAO inhibitors within 5 weeks of discontinuing Salipax can increase the risk of severe adverse events. There have been reports of death in cases where MAO inhibitors were taken shortly after fluoxetine was discontinued. If fluoxetine is prescribed for a long period and/or at a high dose, a longer interval should be considered. Treatment with fluoxetine should not be started for at least 2 weeks after discontinuation of an irreversible MAO inhibitor or for one day after discontinuation of a reversible MAO-A inhibitor.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Paediatric population - Children and adolescents under 18 years of age: Suicide-related behaviours (suicide attempt and suicidal thoughts) and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo. Salipax should only be used in children and adolescents aged 8 to 18 years for the treatment of moderate to severe major depressive episodes and it should not be used in other indications. If, based on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored for the appearance of suicidal symptoms. In addition, only limited evidence is available concerning long-term effect on safety in children&nbsp;<br />and adolescents, including effects on growth, sexual maturation and cognitive, emotional and behavioural developments Although a causal relationship between fluoxetine and the occurrence of such events has not been demonstrated to date, pooled analyses of study data have shown that suicidal thoughts and/or behaviour in children and young adults (aged &lt; 25 years) were increased with antidepressants compared to placebo. It is important that the prescriber discusses carefully the risks and benefits of treatment with the child/young person and/or their parents. Suicide/suicidal thoughts or clinical worsening: In depression, there is an increased risk of suicidal thoughts, self-injury and suicide (or events related to attempted suicide). The risk persists until complete remission occurs. An increased risk of suicidal behaviour may also be associated with other psychiatric illnesses for which Salipax is used as therapy. Patients should be monitored closely during pharmacotherapy. Regardless of the patient&rsquo;s age, physicians should encourage their patients to discuss the emergence of depressing thoughts or feelings with the physician at any time. On the basis of an analysis of controlled studies in which adults with a depressive episode according to the ICD-10 classification (or Major Depressive Disorder MDD, according to the DSM-IV classification) were included, the following risk factors for suicidality with placebo and fluoxetine were established: Before onset of therapy: increasing severity of depression; existing suicidal thoughts. During therapy: worsening of depression; development of insomnia (sleeplessness). Serious psychomotor activation (e.g. agitation, akathisia [see below under &ldquo;Akathisia/psychomotor restlessness&rdquo;], panic) during therapy with fluoxetine also represented a risk factor. If symptoms of this kind are observed before the beginning of therapy or occur during therapy, increased clinical observation or a switch of therapy should be considered. A change in therapeutic regime including a possible withdrawal of medication should be considered in patients whose condition continues to deteriorate or whose emerging symptoms of suicide risk are pronounced, are of sudden onset or were not present among the patient&rsquo;s initial symptoms. Patients and their caregivers must be made aware of the potential risk for&nbsp;<br />suicide within the context of antidepressant therapy and of the urgent necessity to consult the treating physician in such cases. Even after discontinuing treatment, patients must be closely monitored as such symptoms may indicate signs of withdrawal or the start of a relapse. Psychiatric diagnoses other than depression may also be associated with an increased risk of suicidal behaviour. Psychiatric diagnoses like these may also occur in the context of depression. Therefore, the same precautions with regard to suicide risk must be considered with these conditions as with depression. To reduce the risk of overdose, the quantity of capsules prescribed should be as small as possible, depending on the individual patient. Mania/hypomania: Patients should be adequately monitored for the occurrence of manic and hypomanic symptoms until the antidepressant effect sets in (1-3 weeks). Like all antidepressants, fluoxetine must be stopped if a patient enters a manic phase. In studies with fluoxetine in the USA, hypomanic or manic states occurred in 0.1% of patients with depression and in 0.7% of all patients. Haemorrhages: The risk of haemorrhaging, including gynaecological haemorrhages and gastrointestinal haemorrhages may be raised in patients taking SSRIs and SNRIs, including fluoxetine (see &ldquo;Undesirable effects&rdquo;). Caution is therefore advised with the concomitant use of anticoagulants, medicines known to affect platelet function (e.g. NSAIDs, acetylsalicylic acid, atypical neuroleptics such as clozapine, phenothiazines, most tricyclic antidepressants) with fluoxetine and in patients with a history of bleeding. There are reports of cutaneous haemorrhages such as ecchymosis and purpura associated with SSRIs. During treatment with fluoxetine there have been uncommon reports of ecchymosis. Cardiovascular problems: The usual precautions should be taken in patients who have problems with their heart or their blood pressure (see &ldquo;Undesirable effects&rdquo;). QT interval prolongation may occur during fluoxetine treatment. Post-marketing cases of QT interval prolongation and ventricular arrhythmia including torsade de pointes have been reported. Caution must be exercised when administering fluoxetine to patients with diseases such as long QT syndrome, acquired long QT syndrome, (e.g. in cases of concomitant use of a drug that prolongs the QT interval), and positive familial anamnesis for QT interval prolongation, or in other clinical situations that predispose to arrhythmias (e.g. hypokalaemia or hypomagnesaemia) or in cases of raised levels of fluoxetine exposure (e.g. due to hepatic impairments).<br />Interactions/serotonin syndrome: For MAO inhibitors see &ldquo;Contraindications&rdquo;. In rare cases, serotonin syndrome may occur in combination with other serotonergic substances such as triptans, lithium, L-tryptophan and/or neuroleptic medicines. The clinical picture manifests as typical symptoms such as hyperreflexia, tremor, myoclonus, muscle rigidity, mental changes such as restlessness, anxiety, confusion, hallucinations and irritability progressing to delirium and coma, as well as tachycardia, blood pressure fluctuations, hyperthermia, nausea, vomiting and diarrhoea. Akathisia/psychomotor restlessness: The use of fluoxetine has been associated with the development of akathisia, characterized by a subjectively unpleasant and distressing restlessness and need to move, often accompanied by an inability to sit or stand still. This usually occurs during the first weeks of treatment. In patients who develop such symptoms increasing the dose may be detrimental. Withdrawal reactions on discontinuing treatment with a serotonin re-uptake inhibitor: Withdrawal reactions occur commonly on discontinuation of treatment, particularly if the treatment is withdrawn abruptly (see &ldquo;Undesirable effects&rdquo;). In clinical trials adverse events occurred in 60% of patients after discontinuation of treatment in both the fluoxetine and the placebo group. Of these adverse events, 17% in the fluoxetine group and 12% in the placebo group were serious. The risk of withdrawal reactions can depend on several factors, including treatment duration, dose and dose reduction rate. Dizziness, sensory disturbances (including paraesthesias), sleep disorders (including insomnia and vivid dreaming), weakness, agitation or anxiety, nausea and/or vomiting, tremor and headache are the most commonly reported reactions. In general, these symptoms are mild to moderate, but in some patients they may be serious. They usually occur within the first few days of discontinuing treatment. Generally these symptoms regress spontaneously and resolve within 2 weeks. In some people they may persist for longer periods (2-3 months or more). It is therefore recommended that the dose be gradually tapered off over a period of several weeks or months according to the patient&rsquo;s needs when discontinuing treatment with Salipax (see &ldquo;Posology/Administration: Withdrawal symptoms on discontinuing treatment with an SSRI&rdquo;). Skin rash: Since the introduction of fluoxetine hydrochloride, systemic complaints occurring in patients with rashes, possibly related to vasculitis, have been observed. Although these complaints are rare, they may be serious because of their effect on the lung, kidney, or liver. Death has been reported to occur in association with these systemic complaints. Anaphylactic events, e.g. with bronchospasm, angioneurotic oedema and urticaria, have been reported.<br />Upon the appearance of a rash or any other possible allergic reaction for which an alternative aetiology cannot be identified, fluoxetine should be discontinued. Seizures: Seizures are a possible risk with antidepressants. Therefore, as with other antidepressants, treatment with fluoxetine should be instituted with caution in patients with a history of seizures. If seizures occur in a patient for the first time or if the incidence of seizures increases, treatment must be discontinued. Treatment with fluoxetine should be avoided in patients with unstable seizure disorder/epilepsy. Patients with well-stabilized epilepsy must be monitored carefully. Hyponatraemia: Cases of hyponatraemia (some with plasma sodium concentrations lower than 110 mmol/l) have been reported. Most of them occurred in elderly patients and patients taking diuretics or otherwise volume-depleted patients (see &ldquo;Undesirable effects&rdquo;). Glycaemic control: In patients with diabetes mellitus, hypoglycaemia occurred during the treatment with fluoxetine, and hyperglycaemia developed after discontinuation of the drug. Insulin and oral antidiabetic dosage may require adjustment when treatment with fluoxetine is started or discontinued. Physical and psychological dependence: As with other CNS-active agents, physicians should carefully evaluate patients for a history of drug dependence and monitor such patients closely, looking for signs of Salipax abuse (e.g. development of tolerance, dose increase, drug-seeking behaviour). Electroconvulsive therapy: See &ldquo;Interactions&rdquo;. St John&rsquo;s wort (Hypericum perforatum): Undesirable effects may occur with the simultaneous administration of serotonin re-uptake inhibitors and plant-based preparations containing St John&rsquo;s wort. An increase in serotonergic effects such as serotonin syndrome may occur in particular. Mydriasis: There have been reports of mydriasis associated with fluoxetine therapy. Therefore caution is advised when prescribing fluoxetine in patients with increased intraocular pressure or patients at risk for acute closed-angle glaucoma. Because of the long elimination half-lives of the parent drug and its metabolites, changes in dose will not be fully reflected in the plasma within the first weeks, affecting both strategies for titration to final dose and withdrawal from treatment, where applicable (see &ldquo;Pharmacokinetics&rdquo;). The same considerations apply to the possible occurrence of interactions.<br />Caution with respect to the dose is advised in the case of concomitant therapy of fluoxetine with CNS-active agents since they may reciprocally intensify their effects (see &ldquo;Interactions&rdquo;). Because fluoxetine is highly bound to plasma protein, the administration of fluoxetine to a patient taking another drug highly bound to plasma protein (e.g. oral anticoagulants, digitoxin) may cause a shift in plasma concentrations, in turn potentially resulting in adverse reactions (see &ldquo;Interactions&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Co-administration of fluoxetine with other serotonergic active substances (MAO inhibitors, triptans, L-tryptophan, lithium, tricyclic antidepressants, preparations containing St John&rsquo;s wort, etc.) may result in serotonin syndrome (see &ldquo;Contraindications&rdquo; and &ldquo;Warnings and precautions&rdquo;). Drugs that are metabolized by the cytochrome P450 2D6 isoenzyme: As fluoxetine has the potential to inhibit the cytochrome P450 2D6 isoenzyme, a medication taken concomitantly with or within 5 weeks after fluoxetine therapy, and which is metabolized predominantly by the P450 2D6 enzyme (e.g. imipramine, desipramine, risperidone, venlafaxine, haloperidol, clozapine, flecainide, propafenone), in particular any with a narrow therapeutic index, should be introduced gradually, or, alternatively, a lower dose should be selected. Drugs that are metabolized by CYP3A4 or CYP2C: Changes in the blood concentrations of alprazolam, carbamazepine, diazepam or phenytoin, and in some cases symptoms of toxicity, have been observed. A more careful titration of the co-prescribed product and monitoring of clinical status should be considered. Protein binding: Since fluoxetine is highly bound to plasma protein, the concomitant use of fluoxetine with another drug that is highly bound to proteins may change the plasma concentration of both of these drugs. There have been some reports of interactions with digoxin. Therefore, if fluoxetine is administered concomitantly with digoxin, it is recommended that the digoxin levels be monitored. Warfarin and other oral anticoagulants: Altered anticoagulant effects (laboratory values and/or clinical signs and symptoms) without a clear clinical picture but with increased bleeding have been reported rarely when fluoxetine is co-administered with warfarin. Patients receiving a concomitant coumarin preparation should receive careful coagulation monitoring when treatment with fluoxetine is initiated or stopped.<br />Electroconvulsive therapy (ECT): There have been reports of prolonged epileptic seizures in patients on fluoxetine undergoing ECT treatment. Caution should therefore be exercised. Elimination half-life: The long elimination half-lives of fluoxetine and its main metabolite, norfluoxetine, may have potential effects after fluoxetine is discontinued if medications are prescribed that interact with one of the substances. Tryptophan Fluoxetine should not be administered concomitantly with L-tryptophan. See &ldquo;Warnings and precautions&rdquo; regarding the risk of serotonin syndrome. Therefore, simultaneous administration is not recommended. Centrally depressant pharmaceutics The effect of centrally depressant medicines may be enhanced by Salipax. Furthermore, combination with Salipax may result in increased plasma levels of other antidepressants. Lithium Fluoxetine may increase the lithium levels, which should therefore be monitored frequently when these two agents are administered together. See &ldquo;Warnings and precautions&rdquo; regarding the risk of serotonin syndrome. Alcohol Although specific studies have not shown any increase in the effect of alcohol due to fluoxetine, alcohol should be avoided during the treatment. Other substances frequently taken concomitantly Interactions have not been observed so far with simultaneous administration of alcohol, barbiturates, other tranquillizers and hypnotics and thiazide diuretics, blood pressure and pain drugs, thyroid hormones, antihistamines, antibiotics, cimetidine and other antacids. St John&rsquo;s wort (Hypericum perforatum) Undesirable effects may occur with the simultaneous administration of serotonin re-uptake inhibitors and plant-based preparations containing St John&rsquo;s wort.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pregnancy Some epidemiological studies suggest an increased risk of cardiovascular defects associated with the use of fluoxetine during the first trimester. The mechanism is unknown. Overall the data suggest that the risk of having an infant with a cardiovascular defect following maternal fluoxetine exposure is in the region of 2/100 compared with an expected rate for such defects of approximately 1/100 in the general population. Epidemiological data have suggested that&nbsp;<br />the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). The observed risk was approximately 5 cases per 1000 pregnancies. In the general population 1 to 2 cases of PPHN per 1000 pregnancies occur. Fluoxetine should not be used during pregnancy unless the clinical condition of the woman requires treatment with fluoxetine and justifies the potential risk to the foetus. Abrupt discontinuation of therapy should be avoided during pregnancy. If fluoxetine is used during pregnancy, caution should be exercised, especially during late pregnancy or just prior to the onset of labour since some other effects have been reported in neonates: irritability, tremor, hypotonia, persistent crying, difficulty in sucking or in sleeping. These symptoms may indicate either serotonergic effects or a withdrawal syndrome. The time to occur and the duration of these symptoms may be related to the long half-life of fluoxetine (4-6 days) and its active metabolite, norfluoxetine (4-16 days). Breast-feeding Fluoxetine and its metabolite norfluoxetine, are known to be excreted in human breast milk. Adverse events have been reported in breastfeeding infants. If treatment with fluoxetine is considered necessary, discontinuation of breastfeeding should be considered; however, if breastfeeding is continued, the lowest effective dose of fluoxetine should be prescribed. Fertility Animal data have shown that fluoxetine may affect sperm quality (see section 5.3). Human case reports with some SSRI&#39;s have shown that an effect on sperm quality is reversible. Impact on human fertility has not been observed so far.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">As drowsiness and dizziness have been reported with fluoxetine, caution should be exercised when driving and using machines until the individual response to the product is apparent. Concomitant intake of alcohol and other medicines (see &ldquo;Interactions&rdquo;) causes additional impairment of responsiveness and psychomotor activity. Patients should be made aware of this risk accordingly.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The most commonly reported adverse reactions in patients treated with fluoxetine were headache, nausea, insomnia, fatigue and diarrhoea.<br />The list below includes the adverse reactions observed in clinical trials (n = 9297) and from spontaneous reporting. Some of these adverse reactions are consistent with those of other SSRIs. Frequency estimate: Very common ( 1/100 to &lt; 1/1,000 to &lt; 1/100), rare 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000). Blood and lymphatic system disorders Rare: thrombocytopenia, leukopenia, pancytopenia. Immune system disorders Rare: anaphylactic reactions, serum sickness. Metabolism and nutrition disorders Common: decreased appetite (including anorexia), weight loss. Rare: hyponatraemia. Reversible inadequate ADH secretion with hyponatraemia and cerebral oedema have been reported (mostly in elderly patients and with diuretic treatment). Hypoglycaemia has been reported (see &ldquo;Warnings and precautions&rdquo;) Hypokalaemia has been reported.<br />Psychiatric disorders Very common: insomnia (15.0%). Common: anxiety, nervousness, restlessness, tension, decreased libido (including loss of libido), sleep disturbances, abnormal dreams (including nightmares). Uncommon: depersonalization, elevated mood, euphoric mood, abnormal thinking, abnormal orgasm (including anorgasmia), teeth grinding. Rare: manic/hypomanic reaction, hallucinations, agitation. Confusion has been reported. Nervous system disorders Very common: headache (19.9%). Common: attention deficit disorder, dizziness, dysgeusia, lethargy, somnolence (including hypersomnia and sedation), tremor. Uncommon: psychomotor hyperactivity, dyskinesia, ataxia, balance disorders, myoclonus, syncopes. Rare: seizures, akathisia, buccoglossal syndrome, coma. Very rare: memory impairment.<br />Serotonin syndrome has been reported. Eye disorders Common: impaired vision. Uncommon: mydriasis. Cardiac disorders Common msec based on ECG measurements from clinical studies) Uncommon: angina pectoris, myocardial infarct, tachycardia (see &ldquo;Overdose&rdquo;). Rare: cardiac conduction or impulse generation disorders. In clinical studies, there have been rare reported cases of ventricular arrhythmia, including torsade de pointes. Vascular disorders Common: flushing. Uncommon: hypotension. Rare: vasculitis, vasodilatation, thrombophlebitis. Respiratory, thoracic and mediastinal disorders Common: yawning. Uncommon: dyspnoea. Rare: pharyngitis. Nose bleed has been reported. Gastrointestinal disorders Very common: diarrhoea (11.0%), nausea (18.5%). Common: vomiting, dyspepsia, dry mouth. Uncommon: dysphagia. Rare: oesophageal pain. Very rare: pancreatitis. Gastrointestinal bleeding, including bleeding of oesophageal varices, bleeding of gums and mouth, bloody vomit, blood in stools, haematomas (intra-abdominal, peritoneal), bleeding (anal, oesophageal, gastric, gastrointestinal (upper and lower gastrointestinal tract), haemorrhoidal, peritoneal, rectal), haemorrhagic diarrhoea and enterocolitis, haemorrhagic diverticulitis, haemorrhagic gastritis, tarry stools and haemorrhagic ulcers (oesophageal, gastric, duodenal) has been reported. Hepatobiliary disorders Common: abnormal hepatic function tests.<br />Very rare: hepatitis. Skin and subcutaneous tissue disorders Common: rash, urticaria, pruritus, hyperhidrosis. Uncommon: alopecia, increased bruising tendency, cold sweats. Exanthema &ndash; in very rare cases possibly accompanied by systemic symptoms such as joint pain, adenopathy and fever. Rare: angioedema, ecchymosis, photosensitivity reactions. Erythema multiforme has been reported, which can lead to Stevens-Johnson syndrome or toxic epidermal necrolysis (Lyell&rsquo;s syndrome). Musculoskeletal and connective tissue disorders Uncommon: Muscle twitching. Renal and urinary disorders Common: frequent urination (including pollakiuria). Uncommon: dysuria. Rare: urinary retention. Disorders affecting emptying of the urinary bladder have been reported. Reproductive system and breast disorders Common: gynaecological bleeding, erectile dysfunction, ejaculation disorders. Uncommon: sexual dysfunctions (sometimes persisting after discontinuation of therapy). Rare: hyperprolactinaemia (amenorrhoea, breast enlargement, etc.), galactorrhoea Priapism has been reported. General disorders and administration site conditions Very common: fatigue (12.8%) (including asthenia). Common: nervousness, chills. Uncommon: malaise, feeling abnormal, feeling hot, feeling cold. Paediatric population Adverse reactions that have been observed specifically or with a different frequency in this population are described below. Frequencies for these events are based on paediatric clinical trial exposures (n = 610). In paediatric clinical trials, suicide-related behaviours (suicide attempt and suicidal thoughts), hostility (the events reported were: anger, irritability, aggression, agitation, activation syndrome), manic reactions, including mania and hypomania (no prior episodes reported in these patients) and epistaxis, were commonly reported and were more frequently observed among children and adolescents treated with antidepressants compared to those treated with placebo.&nbsp;<br />Isolated cases of growth retardation have been reported from clinical use (See also section 5.1). In paediatric clinical trials, fluoxetine treatment was also associated with a decrease in alkaline phosphatase levels. Isolated cases of adverse events potentially indicating delayed sexual maturation or sexual dysfunction have been reported from paediatric clinical use (see also section 5.3).<br />Systemic symptoms probably caused by vasculitis have been observed very rarely in patients with skin rashes; deaths have been reported in association with these events. It is not known whether these systemic adverse events and the skin rashes have a common cause or are of different pathogeneses. Immunological connections have not been established to date.</p><p dir="ltr">To report any sideeffects: Saudi Arabia:&nbsp;<br />The National Pharmacovigilance and Drug Safety Centre (NPC) Fax: +966-11-205-7662 Call NPC at +966-11-2038222, Exts:2317-2356-2353-2354-2334-2340. Toll free phone: 8002490000 E-mail: npc.drug@sfda.gov.sa Website:www.sfda.gov.sa/npc<br />Other GCC States:&nbsp;-Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Symptoms Cases of overdose of fluoxetine alone usually have a mild course. Symptoms of overdose: nausea; vomiting; epileptic seizures; cardiac dysfunctions, which can range from asymptomatic arrhythmia (including AV junctional rhythm and ventricular arrhythmias) or ECG changes suggesting a QTc interval prolongation to cardiac arrest (including very rare cases of torsades de pointes), pulmonary function disorders, and signs of central nervous system changes, which can range from excitation to coma. Fatal outcomes associated with fluoxetine overdose alone have been extremely rare. Treatment Monitoring of cardiac findings and vital parameters is recommended, together with general symptomatic and supportive measures. No specific antidote is known. Forced diuresis,&nbsp;<br />-Please contact the relevant competent authority.<br />dialysis, haemoperfusion and exchange transfusion will be of little use owing to the large distribution volume of fluoxetine. When treating an overdose, the possibility that several drugs have been taken should be considered.<br />&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">ATC code: N06AB03 Fluoxetine is an antidepressant for oral use which is not chemically related to tri- or tetracyclic or other antidepressants. Based on animal studies it is presumed that fluoxetine, unlike tricyclic antidepressants, has no direct effect on noradrenergic or on dopaminergic neurons. The clinical effect is probably based on the inhibition of serotonin re-uptake into the presynaptic neurons. In subjects who received 30 mg of fluoxetine per day for a week, serotonin uptake into platelets decreased by more than 60%.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Absorption Fluoxetine is readily absorbed (at least 85%) after oral administration. Peak plasma levels occur 6 hours after oral administration. After a single oral dose of 40 mg, peak plasma levels in the range of 15 to 55 ng/ml have been reported after 6-8 hours. After 30 days of administration of 40 mg/day of fluoxetine, plasma concentrations of fluoxetine in a range from 91-302 ng/ml and of norfluoxetine in a range from 72-258 ng/ml have been reported. Simultaneous administration with food slightly delays absorption but does not change total absorption. Metabolism About 3 to 10% of the healthy population has reduced activity of the cytochrome450 isoenzyme P450 2D6 due to a genetic defect. Such individuals are referred to as &ldquo;poor metabolizers&rdquo; of substances such as debrisoquin, dextromethorphan, and tricyclic antidepressants. Many substances, including most of the antidepressants such as fluoxetine and other SSRIs, are metabolized by this isoenzyme; therefore, the pharmacological properties and the relative proportions of the metabolites are changed in &ldquo;poor metabolizers&rdquo;. However, in the case of fluoxetine and its metabolites, the total plasma concentration of the 4 active enantiomers in &ldquo;poor metabolizers&rdquo; is comparable to that in &ldquo;fast metabolizers&rdquo;. Distribution<br />The volume of distribution of fluoxetine and the desmethyl metabolite of fluoxetine (norfluoxetine) is 20 to 45 l/kg of body weight. The plasma protein binding level is about 94.5%. Elimination Fluoxetine is metabolized extensively, so that only small amounts of the unchanged original active substance are excreted into the urine. In investigations with radiolabelled substance, 60% of the radioactivity was recovered in the urine and 16% in the faeces after 5 weeks. A known metabolite is desmethyl-fluoxetine (norfluoxetine), which likewise inhibits serotonin uptake selectively. In healthy subjects, the half-life of fluoxetine is 4-6 days, and the half-life of its desmethyl metabolite (norfluoxetine) is 4-16 days. Plasma clearance of fluoxetine and desmethyl-fluoxetine is about 20 l/h and 9 l/h, respectively.<br />Optimal plasma concentration range Steady-state plasma concentrations are reached after 2-3 weeks. Effective or detectable plasma levels are maintained for 5 half-lives after the discontinuation of the medicinal product.<br />The achieved steady-state concentrations are proportional to the dose but vary considerably from patient to patient. Kinetics in special patient groups For a single dose, the pharmacokinetic profiles of elderly subjects did not differ significantly from those of young subjects. Repeated administration of fluoxetine in patients with renal impairment leads to an accumulation and generally necessitates a dose adjustment. The elimination of fluoxetine is reduced considerably in patients with advanced liver cirrhosis. The half-life of fluoxetine is prolonged on average to 7.6 days (usually 4-6 days) and that of norfluoxetine to 12 days (usually 4-16 days). In all three of these situations, it is recommended that the dose be adjusted (see &ldquo;Posology/Administration&rdquo;). So far there are no data available on humans on the distribution of fluoxetine in the cerebrospinal fluid (CSF) or on fluoxetine crossing the placenta.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">In vitro and animal studies reveal no evidence of carcinogenicity or mutagenicity. Fertility No impairment of fertility has been observed in adult animals at doses of up to 12.5 mg/kg/day (about 1.5 times the maximum recommended dose in mg/m2 in humans). In a juvenile toxicology study in CD rats, administration of 30 mg/kg/day of fluoxetine hydrochloride on postnatal days 21 to 90 resulted in irreversible testicular degeneration and necrosis, epididymal epithelial vacuolation, immaturity and inactivity of the female reproductive tract and decreased fertility. Delays in sexual maturation occurred in males (10 and 30 mg/kg/day) and females (30 mg/kg/day). The significance of these findings in humans is unknown. Rats administered 30 mg/kg also had decreased femur lengths compared with controls and skeletal muscle degeneration, necrosis and regeneration. At 10 mg/kg/day, plasma levels achieved in animals were approximately 0.8 to 8.8 fold (fluoxetine) and 3.6 to 23.2 fold (norfluoxetine) those usually observed in paediatric patients. At 3 mg/kg/day, plasma levels achieved in animals were approximately 0.04 to 0.5 fold (fluoxetine) and 0.3 to 2.1 fold (norfluoxetine) those usually achieved in paediatric patients. Reprotoxicology Embryofoetal development studies in rats and rabbits after administration of up to 12.5 and 15 mg/kg/day, respectively (1.5 and 3.6 times the maximum recommended human dose [MRHD] of 80 mg on an mg/m2 basis) throughout organogenesis revealed no evidence of teratogenicity. In reproduction studies in rats, however, there was an increase in the number of stillborn offspring, a decrease in pup weight and an increase in pup mortality during the first 7 days postpartum when the dams received 12 mg/kg/day (1.5 times the MRHD on an mg/m2 basis) during gestation or 7.5 mg/kg/day (0.9 times the MRHD on an mg/m&sup2; basis) during gestation and lactation. There was no evidence of developmental neurotoxicity in the surviving offsprings of rats treated with 12 mg/kg/day during gestation. The no-effect dose for postpartum rat mortality was 5 mg/kg/day (0.6 times the MRHD on an mg/m&sup2; basis).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Lactose monohydrate, Magnesium stearate, Microcrystalline cellulose, Silica colloidal anhydrous. Capsule: Gelatin, Titanium dioxide (E 171, CI 77891), Iron oxide yellow (E 172, CI 77492), Indigo carmine (E 132, CI 73015), Quinoline yellow (E 104, CI 47005)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months 
The medicinal product may only be used up to the date marked with “EXP” on the package. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Keep this medicine out of the sight &amp; reach of children.</p><p dir="ltr">Do not store above 30&deg;C.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The capsules are sealed into PVC/PE/PVDC-Aluminium blisters (foils) and the blister strips are embossed with the batch number and packed together with the package leaflet into coded cardboard boxes. Capsules with 20 mg: 14, 30 and 100 (B). Not all presentations may be marketed.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Acino Pharma AG, Liesberg, Switzerland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2018.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>